The clinical success of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer has led to a significant expansion in their application, with over 100 clinical trials investigating CDK4/6 inhibitors in combination with chemotherapy, immunotherapy or other targeted therapies across different breast cancer subtypes and other tumor types (Table 1)67. This evidence concerns the gene CDK4 and neoplasm.